<DOC>
	<DOC>NCT00540293</DOC>
	<brief_summary>To evaluate the percentage of Korean dyslipidemic subjects in the total group and each cardiovascular risk group achieving LDL-C target as defined by NCEP ATP Ⅲ criteria at starting doses of 10mg, 20mg and 40mg of atorvastatin after 8 weeks of treatment.</brief_summary>
	<brief_title>Lipitor Korean Atorvastatin Goal Achievement Across Risk Levels Study</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>1. Is a Korean , dyslipidemic outpatient 2. Is eligible for LDLlowering drug therapy at screening and baseline as determined by the following LDLcholesterol (LDLC) cutoff points defined by NCEP ATP Ⅲ: 2. 1 LDLC ≥ 190 mg/dL for subjects with 0 or 1 CHD risk factor 2. 2 LDLC ≥ 160 mg/dL for subjects with 2 or more CHD risk factors and 10 year risk &lt; 10 % 2. 3 LDLC ≥ 130 mg/dL for subjects with 2 or more CHD risk factors and 10 year risk 1020 % 2. 4 LDLC ≥ 100 mg/dL for subjects with documented CHD or CHD risk equivalents (10year risk &gt; 20 %) 3. Has LDLC ≤ 220mg/dL at baseline 4. Has triglyceride level ≤ 600mg/dL at baseline 1. Is pregnant or lactating 2. Has present myopathy or history of myopathy or has personal or familial history of hereditary muscular disorders or any history of rhabdomyolysis 3. Has history of intolerance or hypersensitivity to atorvastatin or other statins 4. Uncontrolled hypertension (i.e. moderate hypertension, sitting systolic BP ≥ 160mmHg and/or diastolic BP ≥ 100mmHg) 5. Has HbAlc &gt; 10% 6. Has any severe disease of has had any major problem or surgical procedure within the 3 months prior to screening that is likely to jeopardize the planned termination of the study. (e.g., any carcinoma, coronary angioplasty, coronary artery bypass graft, cardiac infarct, severe or unstable angina pectoris)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>